Trials / Completed
CompletedNCT01507402
A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786) in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1033(SAR391786) | Administration method A |
| DRUG | REGN1033(SAR391786) | Administration method B |
| DRUG | Placebo | (inactive substance) |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2012-01-10
- Last updated
- 2012-11-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01507402. Inclusion in this directory is not an endorsement.